Microbix Biosystems (TSE:MBX) Stock Passes Above Fifty Day Moving Average – Time to Sell?

Microbix Biosystems Inc. (TSE:MBX)’s share price crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of C$0.25 and traded as high as C$0.30. Microbix Biosystems shares last traded at C$0.30, with a volume of 44,974 shares changing hands.

Microbix Biosystems Trading Up 5.3%

The firm has a market capitalization of C$41.25 million, a price-to-earnings ratio of -7.32 and a beta of 0.70. The company has a current ratio of 5.35, a quick ratio of 5.57 and a debt-to-equity ratio of 27.03. The company has a fifty day moving average price of C$0.25 and a 200-day moving average price of C$0.24.

Microbix Biosystems (TSE:MBX) last announced its quarterly earnings results on Thursday, May 14th. The company reported C($0.01) earnings per share (EPS) for the quarter. The firm had revenue of C$3.38 million for the quarter. Microbix Biosystems had a negative net margin of 38.62% and a negative return on equity of 21.02%. On average, equities research analysts predict that Microbix Biosystems Inc. will post 0.02 EPS for the current year.

Insider Activity

In other news, Director Martin Marino purchased 115,000 shares of Microbix Biosystems stock in a transaction dated Thursday, May 28th. The stock was acquired at an average cost of C$0.28 per share, for a total transaction of C$32,200.00. Following the acquisition, the director directly owned 2,000,167 shares in the company, valued at C$560,046.76. This represents a 6.10% increase in their ownership of the stock. In the last three months, insiders bought 230,500 shares of company stock worth $62,325. 14.00% of the stock is owned by insiders.

About Microbix Biosystems

Microbix develops proprietary biological technology solutions for human health and well-being, with about 90 skilled employees and sales growing from a base of over $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows.